RNA'S of influenza C virus strains.

Cell surface expression of biologically active influenza C virus HEF glycoprotein expressed from cDNA. J Virol (1999) 0.86

Evidence of a soluble substrate for the receptor-destroying enzyme of influenza C virus. Infect Immun (1983) 0.75

Inhibition of influenza C virus replication by actinomycin D, alpha-amanitin, and UV irradiation. J Virol (1979) 0.75

Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell (1985) 3.36

Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J Gen Virol (1971) 2.59

Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures. Virology (1967) 2.41

Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Nature (1998) 2.41

Mechanisms of neutralization of animal viruses. J Gen Virol (1984) 2.16

Review article initial stages in infection with animal viruses. J Gen Virol (1982) 1.87

Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83

An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology (1969) 1.65

Identification of a neutralization-specific antigen of a calf rotavirus. J Gen Virol (1982) 1.64

In vitro activity of norfloxacin against Chlamydia trachomatis. Eur J Clin Microbiol (1983) 1.49

New virus-specific antigens in cells infected with influenza virus. Virology (1969) 1.48

Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol (1969) 1.47

Defective interfering viruses and their potential as antiviral agents. Rev Med Virol (2010) 1.44

The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43

Quantitative relationships between an influenza virus and neutralizing antibody. Virology (1987) 1.37

Neutralization of animal virus infectivity by antibody. Arch Virol (2007) 1.34

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med (1985) 1.29

Electrophoretic separation of influenza virus ribonucleoproteins. J Gen Virol (1981) 1.27

Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol (1994) 1.26

A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology (1997) 1.24

Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol (1990) 1.24

Biophysical studies of a rhinovirus. Extraction and assay of infectious ribonucleic acid. Nature (1966) 1.19

Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology (1975) 1.19

Isolation and structural analysis of influenza C virion glycoproteins. Virology (1981) 1.17

Structural components of influenza C virions. J Virol (1977) 1.17

Insights into neutralization of animal viruses gained from study of influenza virus. Epidemiol Infect (1991) 1.12

Polyadenylic acid sequences in rhinovirus RNA species from infected human diploid cells. J Virol (1975) 1.11

A precursor glycoprotein in influenza C virus. Virology (1979) 1.10

Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis (1996) 1.09

Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus. J Gen Virol (1978) 1.09

The RNAs of defective-interfering influenza virus. Virology (1978) 1.09

Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol (1994) 1.08

Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. J Gen Virol (1982) 1.07

Deletion analysis of a defective interfering Semliki Forest virus RNA genome defines a region in the nsP2 sequence that is required for efficient packaging of the genome into virus particles. J Virol (1998) 1.07

Defective segment 1 RNAs that interfere with production of infectious influenza A virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol (2002) 1.06

A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol (2001) 1.06

Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett (1993) 1.06

Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol (1997) 1.05

Time course of synthesis and assembly of influenza virus proteins. J Virol (1974) 1.05

Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol (2001) 1.04

Heterologous protection of mice from a lethal human H1N1 influenza A virus infection by H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virology (1998) 1.04

Approximately 150 nucleotides from the 5' end of an influenza A segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virology (2000) 1.03

Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Virology (2000) 1.02

Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates. J Gen Virol (1970) 1.02

Characterization of putative defective interfering (DI) A/WSN RNAs isolated from the lungs of mice protected from an otherwise lethal respiratory infection with influenza virus A/WSN (H1N1): a subset of the inoculum DI RNAs. Virology (1995) 1.02

Phosphorylation of influenza virus nucleoprotein in vivo. J Gen Virol (1981) 1.01

Failure of an influenza virus to initiate infection in enucleate BHK cells. J Virol (1974) 1.00

Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J Virol (1992) 1.00

Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology (2000) 0.99

Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS (2000) 0.98

Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine (1996) 0.98

Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol (1990) 0.98

Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses (1995) 0.98

Early events in influenza virus multiplication. II. Penetration of virus into cells at 4 degrees. Virology (1978) 0.97

Fowl plaque virus replication in mammalian cell-avian erythrocyte heterokaryons: studies concerning the actinomycin D and ultra-violet light sensitive phase in influenza virus replication. Virology (1974) 0.96

Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus. J Gen Virol (1989) 0.95

Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. J Infect Dis (1997) 0.95

Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J Gen Virol (1985) 0.95

Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol (1996) 0.94

Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiol Infect (1997) 0.94

Categorization of nucleoproteins and matrix proteins from type A influenza viruses by peptide mapping. Virology (1980) 0.94

Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine (2006) 0.94

Replication of rhinovirus RNA. J Gen Virol (1973) 0.94

Common sequence elements in structurally unrelated genomes of defective interfering Semliki Forest virus. Virology (1994) 0.93

Location of influenza virus M, NP and NS1 proteins in microinjected cells. J Gen Virol (1985) 0.93

High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. J Gen Virol (1997) 0.93

Kinetics of synthesis of influenza virus ribonucleoprotein structures. J Gen Virol (1982) 0.92

Isolation of the influenza C virus glycoprotein in a soluble form by bromelain digestion. Virus Res (1988) 0.92

Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol (1986) 0.91

Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis. J Antimicrob Chemother (1988) 0.91

Competitive binding of neutralizing monoclonal and polyclonal IgG to the HA of influenza A virions in solution: only one IgG molecule is bound per HA trimer regardless of the specificity of the competitor. Virology (1994) 0.91

Mouse androgen-dependent epididymal glycoprotein CRISP-1 (DE/AEG): isolation, biochemical characterization, and expression in recombinant form. Mol Reprod Dev (1995) 0.91

Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology (1977) 0.90

One defective interfering particle per cell prevents influenza virus-mediated cytopathology: an efficient assay system. J Gen Virol (1988) 0.90

Temporal control of transcription of influenza virus RNA. Virology (1975) 0.90

Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine (1999) 0.89

IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology (1993) 0.89

A monoclonal antibody produced during infection which recognizes an epitope of influenza hemagglutinin only in the context of H-2k MHC class I antigen. J Immunol (1993) 0.88

A highly cytopathogenic influenza C virus variant induces apoptosis in cell culture. J Gen Virol (1997) 0.88

IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo. J Gen Virol (1989) 0.88

Hsp70-RAP46 interaction in downregulation of DNA binding by glucocorticoid receptor. EMBO J (2000) 0.88

X-ray crystallographic determination of the structure of the influenza C virus haemagglutinin-esterase-fusion glycoprotein. Acta Crystallogr D Biol Crystallogr (1999) 0.88

A rapid method for the inactivation of virus infectivity prior to assay for interferons. J Virol Methods (1984) 0.88

Defective interfering particles of Semliki Forest virus are smaller than particles of standard virus. J Gen Virol (1984) 0.87

Carbohydrate components of influenza C virions. J Virol (1979) 0.87

Fusion characteristics of influenza C viruses. J Gen Virol (1990) 0.87

All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. J Gen Virol (1995) 0.86

Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. J Gen Virol (2000) 0.86

Mechanisms of neutralization of influenza virus by IgM. J Gen Virol (1985) 0.86

Rhinovirus RNA polymerase: products and kinetics of appearance in human diploid cells. J Virol (1974) 0.85

Different patterns of polyadenylation of rhinovirus: specified RNA during multiplication in human aneuploid and diploid cells. J Gen Virol (1976) 0.85

Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. J Virol Methods (1996) 0.85

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods (1998) 0.85

Flow cytometric analysis of virus-infected cells and its potential use for screening antiviral agents. J Virol Methods (1990) 0.85

[Immunity against poliomyelitis in the German Federal Republic (author's transl)]. Dtsch Med Wochenschr (1979) 0.84